Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|February 27, 2013
Ira Klein, MD, Discusses Quality Measures in Oncology
Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.
Advertisement
Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr Klein says that measurement is a driver for value and healthcare in the future. Quality measures, such as QOPI and HEDIS, allow oncologists to measure how they should be rewarded and recognized for making improvement.
Advertisement
Related to this article
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
5